Next Generation Clinical Trials
We work on re-thinking clinical trials as adaptive, data-rich, and system-oriented processes rather than static protocols. This includes integrating multimodal data, advanced analytics, and AI-supported decision-making while preserving regulatory acceptance.
Our research advances the concept of Fully Individualized Endpoints (FIEPs).
See thus the Whitepaper & Download section of this webpage to download the industrial Whitepaper on FIEPS.
With FIEPS we shift the focus from population averages to patient-specific outcome architectures. We develop methodological frameworks that allow dynamic endpoint modeling based on individual disease trajectories, biomarker constellations, and real-world functional parameters.
By embedding longitudinal real-world data, digital biomarkers, and continuous monitoring streams into trial designs, we aim to transform clinical studies into learning systems rather than isolated experiments. This enables more granular signal detection, earlier therapeutic differentiation, and a more precise understanding of treatment response heterogeneity. At the same time, we work on statistical and governance models that ensure interpretability, robustness, and regulatory credibility of individualized analyses.
Our goal is not only to increase efficiency, but to redefine evidentiary standards for precision medicine in a data-rich research environment.
Ultimately, we see clinical research evolving into an adaptive ecosystem where AI-supported modeling, transparent governance, and individualized evidence generation converge to support next-generation precision therapeutics.